Search

Displaying results 2331 - 2340 of 4859 in total
  1. Drug

    Lodoxamide

    go.drugbank.com/drugs/DB06794
    Approved

    Lodoxamide is a mast-cell stabilizer for topical administration into the eye. Mast-cell stabilizers, first one approved being cromolyn sodium, are used in treatment of ocular hypersensitivity reactions such as vernal conjunctivitis. Thes...

  2. Drug

    Levocabastine

    go.drugbank.com/drugs/DB01106
    Approved

    Levocabastine is a selective second-generation H1-receptor antagonist used for allergic conjunctivitis. Levocabastine was discovered at Janssen Pharmaceutica in 1979.

  3. Drug

    Opicapone

    go.drugbank.com/drugs/DB11632
    ApprovedInvestigational

    [L13772] It is marketed under the brand name Ongentys as once-daily oral capsules.

  4. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [A232563] These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells.

  5. Drug

    Mumps virus strain B level jeryl lynn live antigen

    go.drugbank.com/drugs/DB10316
    ApprovedInvestigational

    It is an active immunization against mumps, which is a common childhood disease.

  6. Drug

    Ceftibuten

    go.drugbank.com/drugs/DB01415
    ApprovedInvestigational

    It is typically used to treat acute bacterial exacerbations of chronic bronchitis (ABECB), acute bacterial otitis media, pharyngitis, and tonsilitis.

  7. Drug

    Ethanolamine oleate

    go.drugbank.com/drugs/DB06689
    Approved

    It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.

  8. Drug

    Buserelin

    go.drugbank.com/drugs/DB06719
    ApprovedInvestigational

    It is used in prostate cancer treatment.

  9. Drug

    Indoramin

    go.drugbank.com/drugs/DB08950
    ApprovedWithdrawn

    It is a selective alpha-1 adrenergic antagonist with no reflex tachycardia and direct myocardial depression action.

  10. Drug

    Larotrectinib

    go.drugbank.com/drugs/DB14723
    ApprovedInvestigational

    It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA.[L4847]. On April 10, 2025, the FDA granted full drug approval.[L52805]